ArticleBMJ open respiratory research2026
Societal and personal financial burden of severe asthma and impact of biologic therapy: a 19-year nationwide cost analysis.
Article in BMJ open respiratory research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Precision medicine in asthma: endotype stratification, biomarker-guided biologics, and emerging therapeutic strategies.Molecular biology reports · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionSevere asthma incurs a financial burden on both patients and societies. However, little is known about the long-term financial burden and impact of biologic therapy.
methodsAll Danish adults initiating biologic therapy for severe asthma between 2016 and 2020 were included and followed retrospectively between 2002 and 2022, both prior to and during biologic therapy. Excess healthcare costs, foregone income and welfare transfers were calculated on an annual basis using a level of education-adjusted, zero-inflated generalised linear model with a gamma distribution and a log-link compared with age, sex, residence and civil status matched comparators.
resultsIn total, 562 patients and 2207 comparators (median age 56 years, 51% female) were included. Excess healthcare costs during the year prior to biologic therapy were €10 590 and foregone income was €5389 per patient. The excess welfare transfers for patients aged 18-64 were €3335.Prior to biologic therapy, pooling of crude annual costs resulted in an accumulation of €59 364 and €44 155 in excess healthcare costs and foregone income per patient, respectively. Patients aged 18-64 had accumulated €32 021 in excess welfare transfers.Biologic therapy was associated with an increase in excess outpatient care costs (€25 938,+398.6%) compared with the year prior to biologic therapy. Outpatient care costs declined to (€14 486,+78.5%) during treatment year 4. Furthermore, at year 4, reductions in hospitalisations (€-2270, -67.7%) and patient-facing medication costs (€-557, -29.7%) compared with the year prior to biologic therapy were observed. Welfare transfers and foregone income were unaffected.
conclusionsIn the present study, patients with severe asthma initiating biologic therapy accumulated a substantial financial burden for both healthcare and welfare institutions, as well as a significant loss of personal income over time. Biologic therapy was associated with increased healthcare costs overall, but did not affect welfare transfers or foregone income.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.